Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

0

For the third consecutive year, 10 students with gastrointestinal diseases will each receive a $10,000 Sotck exchange

LAVAL, QC, July 13, 2022 /PRNewswire/ — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) and its gastroenterology business, Salix Pharmaceuticals (“Salix”), one of the world’s largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, today announced the winners of its 2022 Salix Gastrointestinal Health Scholarship Program. For the third consecutive year, Salix is ​​awarding $10,000 each to 10 students living with gastrointestinal disease.

“Salix is ​​pleased to recognize these 10 outstanding recipients of the Salix Gastrointestinal Health Scholarship who are thriving in their academic journey while living with the challenges of gastrointestinal disease,” said Nicolas Kayel, Vice President, Marketing, Salix. “At Salix, we feel honored to play a small role in the pursuit of higher education for these students, and we look forward to seeing the results of their hard work in the near future.”

The 2022 winners were selected from more than 150 applications. As part of the process, applicants were required to submit essays describing the impact of their gastrointestinal condition on their educational journey, as well as the role played by their healthcare provider in helping them achieve their personal and educational goals. . All scholarship applications have been reviewed by an independent jury.

The Salix Gastrointestinal Health Scholars Program recognizes students in a wide range of educational pursuits, with scholarships in three categories, including the Undergraduate Scholar Awards, for those pursuing undergraduate studies; the Graduate Scholar Awards, for those pursuing graduate studies; and the Working Parent’s Scholar Award, for parents pursuing an undergraduate, vocational/technical, or graduate degree.

Salix Gastrointestinal Health Scholars Program 2022 recipients are:

  • Undergraduate scholarships
    • Maya Greenfield, Lake Oswego, Oregon.Pitzer College
    • Marie Glossop, Loveland, OhioUniversity of Cincinnati
    • Ivy Stevens, Manhattan Beach, California.Bowdoin College
    • Caroline Casola, Orlando, Florida.University of Florida
  • Postgraduate scholarships
    • Hannah Phelps, Encinitas, California.San Diego State University
    • Kaitlyn Ryda, Warren, Mich.University of Oxford
    • Tanner Pearson, Pendleton, Oregon.Drexel University
    • Addison Hillhouse, Jackson, miss. – Vanderbilt School of Nursing
  • Scholarship for working parents
    • Lauren Erback Barnfield, Norridge, Ill.Oklahoma State University
    • Joshua Swimmer, Tecumseh, Mich.Indiana Southern University

“It’s hard to express my gratitude and how truly grateful I am for this opportunity,” said Joshua Swimmerrecipient of the Working Parent’s Award and student at the Indiana Southern University. “I was diagnosed with a lifelong chronic disease, and I never imagined something so positive would come of it. I appreciate everything this will do for me and my family.”

To learn more about the Salix Gastrointestinal Health Scholars program, visit www.salix.com/scholarship.

About Salix
Salix Pharmaceuticals is one of the world’s largest specialty pharmaceutical companies committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve the lives of patients and arm healthcare providers with life-changing solutions for many chronic and debilitating diseases. Salix currently markets its product line to US healthcare providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is ​​headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us at Twitter and LinkedIn.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a diversified global pharmaceutical company whose mission is to improve people’s lives through our healthcare products. We develop, manufacture and market a range of products primarily in the areas of gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health through our participation in approximately 90% in Bausch + Lomb Corporation. With our leading sustainable brands, we deliver on our commitments by building an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

©2022 Salix Pharmaceuticals or its affiliates.
SAL.0084.USA.22

Investor contacts:

Media contacts:

Christina Cheng

Kevin Wiggins

[email protected]

[email protected]




Gianna Scalera


[email protected]

SOURCE Bausch Health Companies Inc.

Share.

Comments are closed.